About us

Presentation

Established in 2009, VIVEXIA is a CRO (Contract Research Organization) focusing on life sciences and health. Our actions and motivation are focused on combatting antimicrobial resistant bacteria. To this aim, we specialized in the creation of humanized or non-humanized preclinical infection models that are designed for the evaluation of anti-infective therapies.

The development of our humanized models allows us to provide reliable and objective preclinical evaluation of the efficacy of treatments. This approach contributes to the selection of the very best drug candidates being clinically evaluated, notably for patients with no further therapeutic options. Our commitment to public benefit is our main motivating force and is bolstered by our close collaboration with the department for Infectious Diseases at the University Hospital in Dijon-Burgundy.

See our in vivo models

Our preclinical plateform

infographie

Our values

Integrity : « Transparency, honesty and high ethical standards guide Vivexia in all its professional practices and all its commitments »

Customer service : « Customer satisfaction is one of our fundamental concerns. We offer a support service that is tailored to suit their requirements. Respectful and constructive communication allows us to build trust and confident customer relations »

Innovation : « Vivexia makes every effort to acquire the most up-to-date savoir-faire and the latest services thanks to an approach focused on constant self-improvement»

Flexibility : « We offer personalized solutions to all our customers that are tailored to their own requirements and we strive to respond to our clients’ requests as promptly as possible »

savoir-faire

In order to support and secure the development of new anti-infective drugs, VIVEXIA offers a complete and tailor-made range of pharmacodynamics models. Depending on your needs, we can create preclinical screening models designed for all stages of the screening process (toxicity, proof-of-concept), as well as more elaborate efficacy models.

Finally, as the development of more than 60% of new molecules is interrupted in phase 2, our expertise aims to offer preclinical models that are as close to human as possible, our main strength being the humanization of infections and of their treatment. The results of this expertise allow us to better characterize the pharmacokinetics / pharmacodynamics profile of drug candidates and therefore offer an improved predictive performance of their potential, which is useful in leading to further clinical developments.

VIVEXIA provides the support from the research and development phase onwards, including in your strategic decision-making. We can intervene in the different stages of the development of your molecules, in order to carry out your early in vitro analysis and/or non-GLP preclinical testing. We always aim to propose models that are suited to your requirements or that are custom-tailored.

Meet our team

The team brings together PhDs, technicians, biologists and clinicians. Also, in order to reinforce its strategic activities (the driver for its development), Vivexia calls upon its network of experts drawn from the academic world and from the industry, creating a strong clinical and scientific grounding. Our close collaboration with infectious diseases specialists, microbiologists and intensive care practitioners allows us to anticipate the type of preclinical models that would be of interest to your research.
The scientific team is reactive and attentive to respond to your specific needs. We are at your service throughout the course of your entire development program.

Delphine
CROISIER

Founder and CEO of Vivexia, she holds a PhD earned through her work on the pharmacodynamics/pharmacokinetics conditions for the emergence and extinction of resistance to fluoroquinolones in Streptococcus pneumoniae. She also holds a doctorate in medicinal pharmacy focusing on the Mutant Prevention Concentrations in the pharmacodynamics of antibiotics.

She has held positions as clinical trial manager for patients suffering from HIV infections and/or viral hepatitis (CHU Dijon).

She is an author or co-author of around thirty peer-reviewed scientific publications.

Delphine
LABROUSSE

She joined the Vivexia team in 2010 and works as a project manager.
She holds a PhD degree in Immunology from the University of Southampton focusing on the role of suppressive myeloid cells in chronic inflammatory diseases. She has also worked as a research associate for GSK Laboratories (Stevenage).

As a result of her great international experience (UK), she is responsible for scientific liaison with English-speaking clients in order to ensure a greater understanding and an effective implementation that is appropriate to the client’s needs.

Sandrine
ALBAC

She studied for her PhD degree at the University of Burgundy, focusing on the early stages involving M Cells in systemic infections of Candida albicans. During the course of her Master’s degree, her work contributed to a patent on the characterization of a new route of metabolism in Candida lusitaniae. She also holds a Master’s degree in administration and company management.

She joined Vivexia in 2015 and works as a Research Engineer; she is most notably involved in R&D programs targeting the development of new preclinical models.

Nelson
ANZALA

With a Master’s degree in Pharmacological Innovation from the Paul Sabatier University in Toulouse, he has worked in the evaluation of new biotherapies in a rabbit model of necrotizing pneumonia induced by a toxin-producing Staphylococcus aureus strain.

He joined Vivexia in 2017 as an assistant engineer and is an expert member of the Ethics Committee on Animal Testing.

Dorian
BONNOT

After 2 years of apprenticeship at Vivexia, he obtained a BTS Anabiotec degree. He then joined the Vivexia team in 2018 and works as a laboratory technician.

He is involved in all current research activities and is in charge of health and safety documents, as well as the establishment of internal quality-control procedures.

Pascal
CHAVANET

Scientific consultant for Vivexia since its establishment and university professor at the Department of Infectiology at CHU in Dijon, he is notably renowned in the field of the pharmacodynamics of antibiotics.

Author of more than 200 international publications on infectious diseases, he has collaborated in countless industrial research and development projects. He is also the main investigator for clinical research projects aimed at improving the treatment of bacterial meningitis and evaluating the meningeal diffusion of new molecules. On this basis, he is a member of the ESGIB-ESCMID (Study Group for Infectious Diseases of the Brain) Group.

Delphine
CROISIER

Founder and CEO of Vivexia, she holds a PhD earned through her work on the pharmacodynamics/pharmacokinetics conditions for the emergence and extinction of resistance to fluoroquinolones in Streptococcus pneumoniae. She also holds a doctorate in medicinal pharmacy focusing on the Mutant Prevention Concentrations in the pharmacodynamics of antibiotics.

She has held positions as clinical trial manager for patients suffering from HIV infections and/or viral hepatitis (CHU Dijon).

She is an author or co-author of around thirty peer-reviewed scientific publications.

Social responsibility at Vivexia

As the activity of our company focuses primarily in the pre clinical evaluation of anti-infective drugs, ethical questions are therefore considered from the very early stages onwards. Every study is subjected to an authorization request from the C2EA Ethics Committee and from the Ministry for Research and Higher Education. All experimental procedures are undertaken in strict accordance with European Union directive 2010/63/EU and are validated by our own veterinarian and the animal welfare department.

Finally, developing the most relevant animal models allows for a more robust and reliable pre clinical evaluation, leading to a reduction in the number of animals required. In addition, our antibiotic resources are preserved and their proper usage in the context of multi-resistant bacterial emergence therefore guaranteed.

Responsabilité sociétale de Vivexia

A mixed business model

We adopt a mixed and combined business operations model:

  • Fee-for-Services that are adapted to our client’s requests (for more information please visit our in vitro and in vivo models) ;
  • Internal R&D programs that target the development of innovative infection models induced by emerging pathogens or allowing the assessment of new therapies;
  • Co-development of new models or collaborative national or international research projects (ANR, FUI etc.).

Laboratory

Our Dijon headquarters is home to both our laboratory and our research unit. In vivo experiments are carried out in the zootechnical center at the faculty of medicine of Dijon-Burgundy, which provides all levels of microbiological confinement required for the use of Class 2 pathogens.

We also work alongside other public and private bodies depending on the requirements and research themes being studied.